This Article Full Text Full Text (PDF) All Versions of this Article: 107/11/1509    most recent 01.CIR.0000056104.49686.4Bv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilkens, H. Articles by Sybrecht, G.W. Search for Related Content PubMed PubMed Citation Articles by Wilkens, H. Articles by Sybrecht, G.W. Related Collections Cardiovascular Pharmacology Pulmonary biology and circulation Pulmonary circulation and disease Endothelium/vascular type/nitric oxide

(Circulation. 2003;107:1509.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Influence of Inhaled Iloprost on Transpulmonary Gradient of Big Endothelin in Patients With Pulmonary Hypertension

H. Wilkens, MD; M. Bauer, MD; N. Forestier; J. König, MD; A. Eichler, MD; S. Schneider; H.J. Schäfers, MD; G.W. Sybrecht, MD

From Medizinische Klinik und Poliklinik, Innere Medizin V (H.W., N.F., A.E., G.W.S.), Klinik für Anästhesiologie und Intensivmedizin (M.B., S.S.); Abteilung Thorax- und Herz-Gefäßchirurgie (H.J.S.); and the Institut für Medizinische Biometrie (J.K.), Epidemiologie und Medizinische Informatik, Universitätskliniken des Saarlandes, Homburg/Saar, Germany.

Correspondence to Dr H. Wilkens, Medizinische Klinik und Poliklinik, Innere Medizin V, Universitätskliniken des Saarlandes, D-66421 Homburg/Saar. E-mail inhwil{at}med-rz.uni-saarland.de

Background— The pulmonary circulation is an important site for the production and clearance of endothelin (ET)-1, a potent vasoactive and mitogenic peptide. In healthy individuals, 40% to 50% of circulating ET-1 is removed on each passage through the lungs resulting in an arteriovenous ratio of <1, whereas many patients with pulmonary arterial hypertension (PAH) have ratios >1, indicating reduced clearance or increased release of endothelin. The influence of inhaled prostanoids on endothelin clearance is unknown.

Methods and Results— In a prospective investigation, plasma concentrations of big endothelin-1 (big ET-1, Elisa) were measured in 15 patients with pulmonary hypertension undergoing right heart catheterization with iloprost inhalation (4 m, 11 f, aged 35 to 75 years, mean pulmonary arterial pressure (PAPm) 54±2.3 mm Hg, pulmonary vascular resistance (PVR) 1061±141 dyn x sec x cm^-5). There was a significant transpulmonary gradient for big ET-1 with 31% ±11% higher concentrations in the radial artery than in the pulmonary artery (P<0.001). After inhalation of iloprost a significant decrease in the AV-ratio from 1.31±0.11 to 0.92±0.06 (P<0.007) was observed. The pulmonary net release of 3.10±0.65 pmol/min big ET-1 at baseline decreased to -1.24±1.32 pmol/min (P=0.013) within 15 minutes indicating a restored balance. Patients under long-term treatment with iloprost (n=7) tended to have a lower net release and AV-ratio for big ET-1 than patients without pretreatment.

Conclusion— An increase in pulmonary clearance of big-ET could be a mechanism contributing to the beneficial effects of inhaled prostanoids in the treatment of PAH.

Key Words: hypertension, pulmonary • endothelin • prostaglandins

This article has been cited by other articles:

				G. Warwick, P. S. Thomas, and D. H. Yates Biomarkers in pulmonary hypertension Eur. Respir. J., August 1, 2008; 32(2): 503 - 512. [Abstract] [Full Text] [PDF]

				T. Kramm, B. Eberle, S. Guth, and E. Mayer Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 882 - 888. [Abstract] [Full Text] [PDF]

				S. E Baker and R. H. Hockman Inhaled Iloprost in Pulmonary Arterial Hypertension Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274. [Abstract] [Full Text] [PDF]

				A. Peacock, R. Naeije, N. Galie, and J.T. Reeves End points in pulmonary arterial hypertension: the way forward Eur. Respir. J., June 1, 2004; 23(6): 947 - 953. [Abstract] [Full Text] [PDF]

				N. Galie, A. Manes, and A. Branzi The endothelin system in pulmonary arterial hypertension Cardiovasc Res, February 1, 2004; 61(2): 227 - 237. [Abstract] [Full Text] [PDF]